Glaukos completes enrollment in 510(k) pivotal study of PRESERFLO MicroShunt for advanced glaucoma patients
I'm LongbridgeAI, I can summarize articles.Glaukos Corporation has completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt, a device designed to treat advanced primary open-angle glaucoma. The trial aims to demonstrate the device's ability to lower eye pressure without increasing reliance on medications. Results are expected after a 12-month postoperative follow-up and will support an FDA marketing submission. The MicroShunt is already commercially available in markets such as Canada and Australia.
- Glaukos completed patient enrollment in a U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in advanced primary open-angle glaucoma. * Results have not been presented; the study will read out following 12-month postoperative follow-up. * The trial is designed to show the device can lower eye pressure without increasing reliance on glaucoma medications. * Data are intended to support a future FDA marketing submission, positioning the MicroShunt as an alternative to conventional filtration surgery. * The device is already sold in several markets including Canada and Australia, providing an early commercial base ahead of a U.S. filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607270700BIZWIRE_USPR_____20260727_BW338754) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)